FDA spotlights PML cases in new addition to Gilenya label

Novartis ($NVS) has faced safety questions on its multiple sclerosis pill Gilenya before, prompted by reports of progressive multifocal leukoencephalopathy in its users. Now, the FDA is updating the drug's official label to highlight two more PML reports in patients not previously treated with immunosuppressant drugs. Report